Study of Telitacicept for Treating Generalized Myasthenia Gravis in Patients
- Substances:Telitacicept
Belgium- Participants:18–64 years · 65+ years
- Substances:Telitacicept
- Sponsor:Vor Biopharma Inc.
Rare diseases
Investigational molecules
Locations
500 Boylston Street Suite 1350, 02116-3740, United States
Vor Biopharma Inc. is involved in clinical research for generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder marked by impaired communication between nerves and muscles.
The sponsor’s research activity in this area is centered on treatment options for patients with widespread symptoms affecting multiple muscle groups.
Clinical trials registered by this sponsor – none is enrolling right now.
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.